Search

Additional file 19. Supplementary material of "Multi-label transcriptional classification of colorectal cancer reflects tumour cell population heterogeneity.

Additional file 8: Figure S1. Distribution of genes detected in scRNA-seq data of patient derived organoidswith a coverage of 1 to 5 reads for transcripts. Figure S2. Distribution of Pearson correlation values obtained by analysing unmatchedand matchedCRC PDO bulk / PDO pseudo-bulk pairs. Figure S3. CRIS classification of CRC single sample data from GSE132465, pseudo-bulk, and at scRNA-seq resolution. B) represents the distribution of CRIS distances evaluated on each single cell, grey points. Black points represent distances for cells with significant assignment. Red dots, represent the class distances on pseudo-bulks. C) waterfall of CRIS distances for significant assigned cells. Supplementary Fig. 4. Distribution of the CRIS classes on testing samples of TCGA and PDX datasets, using LSVM single-labeland adapted to multi-label. The TCGA dataset has 169 samples, while the PDX dataset 550 samples. Figure S5. Forest plots for LSVM-based models. Along y-axis, an identifier number for each test is reported. For each test, the odds ratioand its confidence interval are shown; the numeric label annoated on each odds ratio represents the p-value. Other details of the testsare listed below the corresponding plot.

RNA interference-mediated downregulation of TNKS phenocopies pharmacologic inhibition in impairing cell invasion and migration. (PPTX 243 kb)

β-catenin/TCF-dependent readouts are not substantially influenced by TNKS inactivation. (PPTX 69 kb)

TNKS is recruited to cortical areas in migrating cells. (PPTX 2189 kb)

The microtubule network is stabilized by TNKS pharmacologic neutralization. (PPTX 1715 kb)

TNKS silencing prevents the reallocation of APC at cortical sites. (PPTX 354 kb)

TNKS inhibition does not substantially affect cell proliferation. (PPTX 68 kb)

β-catenin/TCF-dependent readouts are not substantially influenced by TNKS inactivation. (PPTX 69 kb)

TNKS silencing stabilizes the microtubule network. (PPTX 687 kb)

Synthesis scheme for JNJ-BJ. (DOCX 80 kb)

RNA interference-mediated downregulation of TNKS phenocopies pharmacologic inhibition in impairing cell invasion and migration. (PPTX 243 kb)

Centrosome relocation is perturbed by TNKS silencing. (PPTX 239 kb)

Multiple myeloma is the second most common hematologic malignancy. It accounts for 20,580 new cancer cases in the USA in 2009, including 11,680 cases in men, 8,900 cases in women, and 10,580 deaths overall. Although the disease remains still incurable, outcomes have improved substantially over recent years thanks to the use of high-dose therapy and the availability of novel agents, such as the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. Various trials have shown the advantages linked to the use of novel agents in the transplant and not-transplant settings. In particular, this paper will present an overview of the results achieved with lenalidomide-containing combinations in patients eligible for high-dose therapies, namely, young patients. The advantages obtained should always be outweighed with the toxicity profile associated with the regimen used. Therefore, here, we will also provide a description of the main adverse events associated with lenalidomide and its combination.